The mechanisms and pathways regulating self-renewal and differentiation of MaSCs are of great interest for their potential application in the prevention and treatment of breast cancer 1 . TICs, also known as cancer stem cells, play key roles in treatment resistance, recurrence, and metastasis of breast cancer and other malignant diseases [2] [3] [4] , and may share similar features and regulatory mechanisms with normal stem cells. However, despite significant progress in recent years, the molecular basis underlying the putative link between TICs and normal tissue stem cells remains poorly characterized.
Recent studies have highlighted several transcription factors, such as Bmi-1, Oct1, p53, Snail, Gata3 and Elf5, as key regulators with multiple roles in mammary cell fate determination, stem cell activity, and tumour initiation and progression [5] [6] [7] [8] [9] [10] . Transformation-related protein 63 (Trp63, or p63) is a member of the p53/p63/p73 family of transcription factors that is highly expressed in stratified epithelia such as cervix, skin, prostate and breast 11 . p63 proteins include isoforms of two main groups: those possessing a full-length transactivation domain (referred to as the TA isoforms), and those lacking this domain (the N isoforms) 11, 12 . The role of p63 in development and cancer has remained perplexing largely because of these multiple isoforms of p63. Both increased and reduced expression of p63 have been observed in human cancers 13, 14 . Disparate results regarding the role of p63 in cancer have also been reported using different p63 mouse models 15, 16 . It has been suggested that the TA isoforms are most similar to p53 in their tumour-suppressive functions 17, 18 and the Np63 isoforms generally exhibit oncogenic functions, such as in skin and bladder 19, 20 . In the normal mammary gland, Np63 is shown to be expressed at much higher levels than TAp63 (refs 21-24) . Recent studies have also revealed a role for Np63 in maintaining basal lineage cell fate in vitro in mammary epithelia cells 25 . Despite these findings, rigorous functional studies of p63 isoforms in regulating MaSCs and TICs remain scarce and further investigation is warranted.
The role of p63 in regulating epithelial homeostasis has been linked to its influence on several signalling pathways such as Notch, Wnt and Shh (refs 26-29) , which have all been shown to be important regulators of normal and cancerous stem cells 30, 31 . The extent to which these pathways are involved in p63-dependent regulation of Table showing reconstitution rate of the mammary gland over successive generations after transplantation of 10,000 unsorted MECs transduced with control or Np63-expressing lentiviruses. * P < 0.05, * * P < 0.01 by Student's t-test. Scale bars, 40 µm in c, 1 mm in f and g, 2 mm in i, and 3 mm in j. Uncropped images of blots are shown in Supplementary Fig. 9 . Supplementary Fig. 9 . mammary epithelium remains unclear. Notably, Wnt signalling has been shown to be instrumental for mammary gland development and MaSC activity [32] [33] [34] . Aberrant Wnt signalling has also been reported in tumours from patients with different types of cancer such as colorectal cancer, hepatocellular carcinoma, hepatoblastoma and breast cancer [35] [36] [37] . In breast cancer, Wnt signalling has been found to be particularly hyperactive in the basal-like subtype and predicts poor prognosis 38, 39 . However, what regulates Wnt signalling in normal MaSCs and the highly aggressive basal subtype of breast cancer remains poorly understood. In general, oncogenic mutations in Wnt pathway components, such as β-catenin, APC and Axin, are relatively rare in breast cancer 40, 41 . In this study, we dissect the role of different p63 isoforms in MaSCs and breast cancer TICs. Using multiple isoform-specific molecular and genetic tools and models, we demonstrate the important function of Np63 in regulating MaSC activity and promoting breast cancer initiation in basal-like breast cancer through direct transcriptional activation of Fzd7 and subsequent enhancement of Wnt signalling. (Fig. 1a-d and Supplementary Fig. 1a ). 80-100%, 30-80%, 0-30% and no reconstitution. * P < 0.05 by Student's t-test in a and c. In b,e and g, n = number of mammary fat pad injections as indicated in tables, P value was obtained by Pearson's χ 2 test using ELDA software. Scale bars, 1 mm in d and f, and 2 mm in h, respectively.
RESULTS

Np63 but not TAp63 regulates MaSC activity
To explore the functional importance of Np63 in MaSCs, Np63-and TAp63-expressing lentiviral vectors were transduced into MECs (Fig. 1e and Supplementary Fig. 1b,c) , and robust ectopic overexpression of both genes was confirmed ( Supplementary  Fig. 1d,e) . Interestingly, overexpression of Np63, but not TAp63, in P4 cells led to a significant increase in MaSC activity, as reflected by increased reconstitution and ductal outgrowth after transplantation into cleared fat pad ( Fig. 1f and Supplementary Fig. 1f,g ). Importantly, Np63 overexpression also conferred stem cell activity to P5 cells, indicating that Np63 is able to induce luminal cells to enter a stemlike state ( Fig. 1g and Supplementary Fig. 1h ,i). We next measured Np63-induced enhancement of MaSC activity using a more stringent competitive reconstitution assay 8, 34 ( Supplementary Fig. 1j ). Transplantation of Np63-dsRED + and control-GFP + P4 cells in an equal ratio resulted in outgrowths that were predominantly dsRED + , suggesting that Np63-overexpressing MaSCs had a competitive growth advantage over their normal counterparts (Fig. 1h,i) . In contrast, overexpression of TAp63 did not augment MaSC ability (Fig. 1h,i) . Collectively, these studies demonstrate that Np63, but not TAp63, promotes MaSC activity.
We next examined the function of Np63 in different subpopulations of luminal cells. CD61 has been described to be a luminal progenitor marker among luminal epithelial cells 42 
(P5). Overexpression of Np63 increased the repopulating frequency in both P5-CD61
+ and P5-CD61 − populations ( Supplementary  Fig. 2a,b) . Furthermore, immunostaining of three-dimensional (3D) Matrigel colonies and mammary outgrowths from Np63-overexpressing CD61
+ and CD61 − luminal subsets with cytokeratin 14 and 8 (K14 and K8) markers revealed cells from both basal and luminal lineages, suggesting the capability to differentiate into both lineages ( Supplementary Fig. 2c,d ). Interestingly, Np63 overexpression failed to significantly increase reconstitution in Lin − CD24 low (P6) stromal-enriched cells ( Supplementary Fig. 2e ,f), suggesting that its function is restricted to epithelial cells.
Np63-overexpressing outgrowths showed increased tertiary branching and an increased percentage of Ki67-positive cells ( Fig. 3f,g ).
We next investigated the effect of Np63 and TAp63 overexpression on colony-forming abilities. A significant increase in clonogenic potential was observed in MaSCs overexpressing Np63 compared with TAp63 in primary 3D Matrigel cultures ( Supplementary  Fig. 4a,b) . Monochromatic colonies formed by mixed P4 cells from actin-GFP and actin-DsRed mammary glands confirmed that each colony originates from single cells instead of aggregates (Fig. 1j) . We next performed serial passage and transplantation assays both in vitro and in vivo, which confirmed that Np63 can induce MaSC selfrenewal activity (Fig. 1k,l and Supplementary Fig. 4c ).
To further test whether the observed Np63 phenotype is dependent on its transcriptional activity, we tested a DNA-binding mutant (MT) form of Np63 in P4 cells. Although similar levels of MT and wild-type (WT) Np63 were overexpressed in these cells ( Supplementary Fig. 4d,e) , only WT Np63 induced the increased MaSC activity as shown by the Matrigel colony formation and reconstitution assays ( Supplementary Fig. 4f-h ). In e and o, n = number of mammary fat pad injections as indicated in the table. P value was obtained by Pearson's χ 2 test using ELDA software. Uncropped images of blots are shown in Supplementary Fig. 9 .
Loss of Np63 leads to MaSC deficiency
To complement our gain-of-function analysis of Np63 as described above, we next used a Np63-GFP knock-in loss-of-function mouse model 43 ( Supplementary Fig. 5a ). As homozygous loss of Np63 leads to embryonic lethality, we performed all of our experiments using heterozygous Np63 gfp/+ animals with reduced expression of Np63 (Fig. 2a,b) . We observed a significant reduction of ductal elongation in Np63 gfp/+ mammary glands compared with those of WT counterparts at both 6 weeks and 9-10 weeks ( Fig. 2c and Supplementary Fig. 5b-d ). FACS and limiting dilution assays also demonstrated a reduced number and activity of MaSCs in Np63 gfp/+ mice ( Fig. 2d-f and Supplementary Fig. 5b,d,e) .
To further evaluate the loss-of-function effect of individual p63 isoforms, we next performed isoform-specific knockdown (KD) of Np63 and TAp63 in mouse MECs (Fig. 2g-i) . As expected, only Np63 KD led to significantly reduced mammosphere numbers, suggesting decreased stem cell activity (Fig. 2j) . Together, these results indicate that Np63 but not TAp63 is a crucial regulator of normal MaSCs.
To obtain a global view of the molecular events underlying the loss of the Np63 phenotype, we next performed a microarray analysis of control and Np63 gfp/+ MECs (Fig. 2k) . Gene-set enrichment analysis (GSEA) demonstrated that MaSC-enriched genes were significantly downregulated in the transcriptome of Np63 gfp/+ MECs (Fig. 2k) , a finding consistent with the decreased MaSC activity of Np63 gfp/+ MECs.
Wnt receptor Fzd7 is a Np63 target that mediates its effect on MaSCs
Multiple lines of evidence suggest that Notch, Wnt and Shh signalling is important for stem cell activity in different tissues 31 . Therefore, we next investigated whether any of these pathways were altered in Np63 gfp/+ MECs. GSEA demonstrated that only Wnt signalling gene sets were significantly downregulated in both MECs and P4 cells from Np63 gfp/+ mice compared with WT (Fig. 3a) . To directly test whether Np63-regulated Wnt signalling is important for MaSC function, we performed colony-formation assays with and without the Wnt signalling inhibitor Dickkoph 1 (Dkk1). Dkk1 inhibited the Np63-mediated increase in colony formation of both primary cells and cells in subsequent serial passages ( Supplementary Fig. 5f-h ), suggesting that Np63-induced MaSC activity is indeed mediated by Wnt signalling. Moreover, a Wnt reporter assay confirmed the positive regulation of canonical Wnt signalling in MaSCs by Np63 but not TAp63 (Fig. 3b) .
We next sought to identify Wnt signalling genes regulated by Np63. Transcriptome profiling indicated that nine Wnt pathway genes, including several Wnt ligands and receptors, have reduced expression in Np63 gfp/+ P4 cells compared with WT (Fig. 3c) . Quantitative real-time PCR (qRT-PCR) analysis confirmed four out of these nine genes to be significantly downregulated in Np63 gfp/+ MaSCs (Fig. 3d) mediated KD of p63 in primary MECs (Fig. 3e) . Notably, both Wnt5a and Fzd7 belonged to the 'enrichment cores' of two WNT gene signatures used in the GSEA study (Supplementary Fig. 6a ). Therefore, we reasoned that Np63 may regulate MaSCs through direct activation of either Fzd7 or Wnt5a, or both. To further investigate this possibility, we next performed isoform-specific KD of p63. Reduced levels of Fzd7 and not Wnt5a were observed with Np63 KDs but not TAp63 KDs (Fig. 3f,g ). Conversely, enforced overexpression of Np63 but not TAp63 led to a significant increase in the expression of both WNT5A and FZD7 in the HMLE human mammary epithelial line (Fig. 3h, right panel, and Supplementary Fig. 6b ). Interestingly, only FZD7 showed strong activation by Np63 within 48 h post-infection, suggesting it to be a direct target of Np63 (Fig. 3h, left panel) . Indeed, examination of chromatin immunoprecipitation sequencing (ChIP-seq) data from human keratinocytes 44 revealed p63 binding in a conserved active enhancer region ∼40 kilobases (kb) upstream from the FZD7 gene (Fig. 3i, region highlighted in red) . To confirm binding of p63 to this enhancer, we performed ChIP analysis of primary human MECs and primary mouse MMTV-Wnt1 tumour cells using anti-p63 antibodies, and observed strong enrichment of the FZD7 enhancer in p63-bound chromatin (Fig. 3j,k) . We next performed luciferase assays using a reporter driven by the FZD7 enhancer, together with Np63, TAp63, or a DNA-binding mutant of Np63. As expected, only Np63 overexpression significantly activated FZD7 enhancer reporter activity in HMLE cells and immortalized murine MECs (ref. 45 ; Fig. 3l,m) .
We next determined the direct functional importance of Fzd7 in MaSCs. Fzd7 overexpression in P4 cells led to increased MaSC activities, phenocopying the effect of Np63 (Fig. 4a,b) . Moreover, overexpression of Fzd7 in Np63 gfp/+ P4 cells was able to at least partially rescue the reduced MaSC phenotype close to that of the WT levels in both colony-formation (Fig. 4c,d ) and repopulation assays (Fig. 4e,f) . Similarly, Fzd7 overexpression rescued MaSC activity in Np63-KD MECs ( Supplementary Fig. 6c,d) . Finally, Fzd7 KD attenuated the increase in MaSC activity driven by Np63 overexpression (Fig. 4g,h ). Collectively, these data suggest that Np63-induced MaSC activity is primarily mediated by increasing the expression of the Wnt signalling receptor Fzd7.
Positive correlation of Np63 and Fzd7 expression in human tumours
To evaluate the relationship between Np63 and overall WNT signalling activity in the clinical setting, we interrogated two human breast cancer data sets 46, 47 . Consistent with the Np63 gfp/+ mouse data (Fig. 3a) , GSEA of the EMC286 data set revealed a significant enrichment of WNT signalling gene sets in human breast tumour samples predicted to have high Np63 activity on the basis of their Np63-specific gene signature score ( Supplementary  Fig. 6e ). High Np63 signature expression is preferentially associated with the basal subtype over the luminal subtype (Fig. 5a ) and the Np63 signature score showed a positive correlation with FZD7 expression (Supplementary Fig. 6f ). Further confirming this observation, analysis of a TCGA data set containing isoform-specific RNA-Seq data 46 revealed ∆Np63 as the primary p63 isoform expressed in tumours (Supplementary Fig. 6g ) and a strong positive correlation between Np63 and FZD7 mRNA levels (Fig. 5b) . Consistently, immunostaining of Np63 and FZD7 in 12 primary human breast tumours revealed a similar positive correlation (r = 0.47, P = 0.06) based on staining intensity score (Pearson correlation; Fig. 5c ), and both proteins were found to be upregulated in the triple-negative (TN) breast tumours compared with the luminal subtype (P = 0.04 and P = 0.03 for Np63 and FZD7 respectively; Fig. 5c ). To further test the functional link between p63 and canonical Wnt signalling, we next performed Wnt reporter assays in the MDA-MB-231 breast cancer cell line. p63 KD led to a significant reduction of FZD7 protein level ( Supplementary Fig. 7a ), as well as inhibition of WNT3A-induced canonical Wnt signalling (Fig. 5d) , to an extent comparable to FZD7 KD. As expected, p63 KD also led to reduced tumour engraftment of TN MDA-MB-231 and SUM-1315 cells (Supplementary Fig. 7b,c) . Furthermore, KD of Np63 but not TAp63 (Fig. 5e-h ) led to significant inhibition of Wnt signalling (Fig. 5i) , similar to pan-p63 KD using short hairpin RNAs (shRNAs) targeting sequences encoding the DNA-binding domain (DBD). Importantly, Np63 but not TAp63 KD reduced tumour incidence to a degree similar to pan-p63 KD or FZD7 KD (Fig. 5j,k) , and resulted in reduced FZD7 expression (Fig. 5f,g ).
To further strengthen the molecular connection between Np63 and FZD7 in human breast cancer, we next investigated the functional role of Np63 and Fzd7 in three patient-derived xenografts (PDXs) of human TN breast tumours. Immunohistochemistry (IHC) on PDX tumours indicates strong expression of Np63 and FZD7 in all three PDX tumours compared with weak TAp63 staining in PDX-1 and PDX-3 tumours 48 ( Supplementary Fig. 7d ). Lentiviral KD of Np63 and FZD7 in PDX tumours (PDX-2 and PDX-3) significantly reduced tumorsphere formation compared with control and TAp63 KD (Fig. 5l-p) . Taken together, our data suggest that the Np63-Fzd7-Wnt signalling axis is conserved in human breast cancer and regulates tumour formation.
Np63 induces tumour-initiating ability in basal-like mouse mammary tumours
To more rigorously test the functional role of Np63-regulated Fzd7 expression in controlling TIC activity of basal-like breast cancer cells, we next performed IHC on tumours derived from three different mouse models representing different subtypes of breast cancer based on gene expression profiling-MMTV-Wnt1 (basal), MMTV-Myc (mixed basal and luminal) and MMTV-PyMT (luminal) 49, 50 . As expected, higher expression of Np63 and Fzd7 was observed in the basal subtype (MMTV-Wnt1) compared with luminal subtype (MMTV-PyMT) tumours ( Supplementary Fig. 7e,f) , further supporting observations from human breast cancers. Modest staining for Np63 and Fzd7 was also observed in MMTV-Myc tumours. In contrast, no positive TAp63 staining was observed in any tumour subtype ( Supplementary Fig. 7e ). Functionally, p63 KD in MMTVWnt1 tumour cells significantly reduced tumorsphere formation in vitro (Fig. 6a,b) and increased tumour latency and decreased tumour volume in vivo (Fig. 6c-e) .
A small subset of CD45 − CD24 + Thy-1 + cells in the MMTV-Wnt1 tumours is thought to be endowed with TIC properties 51 . We found that both p63-KD and Fzd7-KD tumour cells showed a significant reduction of the Thy-1 + population (Fig. 6f,g ). Fzd7 expression was significantly decreased (Fig. 6h ) after p63 KD, further suggesting Fzd7 as a direct target of Np63. Consistent with the isoform-specific role of Np63 in regulating TIC activity, KD of Np63 but not TAp63 reduced Fzd7 expression and tumorsphere formation (Fig. 6i-k) .
We next directly investigated whether Fzd7 has any functional significance in Wnt1-driven tumour cells both in vitro and in vivo. Interestingly, Fzd7 KD in Wnt1 tumour cells decreased tumorsphere formation (Fig. 6l) , phenocopying Np63 KD. Furthermore, the reduced tumorsphere-forming activity of Np63-KD Wnt1 tumour cells was rescued by ectopic expression of Fzd7 (Fig. 6l) . Corroborating the in vitro data, Fzd7-KD cells showed increased tumour latency and significantly reduced tumour burden, phenocopying Np63 KD (Fig. 6m-o) . However, one potential caveat of using the MMTVWnt1 tumour model to investigate the p63-Fzd7 regulatory axis is that Wnt1-induced tumours may depend on Fzd7 regardless of p63. To circumvent this problem, we performed p63 and Fzd7 KD in both MMTV-Myc and Blg-Cre-Brca1 f/f p53 +/− tumours that are not induced by Wnt. Np63 KD in MMTV-Myc tumours yielded similar results to Np63 KD in MMTV-Wnt1 tumours, such as decreased tumorsphere formation, increased tumour latency, and significantly reduced tumour burden (Fig. 7a-i) . Furthermore, Fzd7 KD also led to reduced tumorsphere-forming ability of these two additional basal-like mouse mammary tumour models (Fig. 7j,k) , suggesting a common role for Fzd7 in regulating basal-like tumours.
To more definitively examine the role of Np63 in basal-like breast cancer, we generated MMTV-Wnt1; Np63 gfp/+ mice. Expression of the Wnt1 oncogene under the MMTV promoter led to extensive ductal hyperplasia and expansion of the MaSC-enriched basal (P4) population 32 , a phenotype that is reduced in Np63 gfp/+ mice (Fig. 8a,b) . Consistently, MMTV-Wnt1; Np63 gfp/+ MECs exhibited reduced MaSC activity (Fig. 8c-e) . Reduced expression of Np63 in Np63 gfp/+ mice also led to a significant delay in tumour initiation as well as a reduction of Fzd7 and basal marker K14 expression ( Fig. 8f and Supplementary Fig. 8a-c) . These results indicate that Np63 activity contributes to the regulation of the TIC population in Wnt1-induced pre-neoplasia and basal tumours.
DISCUSSION
p63 is a member of the p53 superfamily that is structurally similar but functionally distinct from p53 (ref. 11). The function of p63 has also been extended from regulating stem cell activity, differentiation, growth and survival to other aspects of cancer biology, such as cell adhesion 52 and metastasis 13 . Despite these advances, the functional role of p63 in regulating MaSCs remains unclear. Overexpression of Np63 in unsorted MECs in vitro was found to result in an increase in basal cells but reduced regenerative potential by antagonizing Notch 25 . In the present study, we used isoform-specific lentiviral overexpression in primary MaSCs to show that Np63 overexpression promotes MaSC activity and genetic ablation of even one allele of Np63 reduces MaSC function in vivo. We also demonstrated that the Np63 isoform regulates these phenotypes through upregulating Wnt signalling whereas the TAp63 isoform does not have such effects, highlighting the importance of isoform-specific studies of the p63 gene in development and cancer. Furthermore, Np63 overexpression can convert luminal cells to a stem-like state, supporting the emerging concept of reversible plasticity in epithelial cell fate 3, 4, 8, 25, 53 . The role of Np63 in breast cancer remained largely unclear despite some recent exploration of p63 functionality in breast cancer initiation 54 . We establish a functional role for Np63 in regulating TICs in basal breast cancer, an aggressive form of breast cancer with few available treatment options 55, 56 . The Np63-specific gene signature is highly enriched in this subtype and Np63-specific KD severely diminishes TIC activity of basal breast cancer cells. Taken together, our studies establish Np63 as a functional driver of normal and malignant stem cells in the mammary epithelium (Fig. 8g) .
FZD7 is one of the most abundant Frizzled family proteins expressed in basal/TN breast cancer, and has been shown to promote proliferation of these tumours 38, 57, 58 . However, the role of Fzd7 in mammary gland development and the mechanism of its elevated expression in basal/TN breast cancer remain poorly defined. We identified Fzd7 as a direct transcriptional target of Np63 and demonstrated that Fzd7 functions downstream of Np63 in regulating MaSC activity. Despite the strong correlation of Fzd7 and Np63 expression in clinical samples, we do not rule out the possibility that Fzd7 expression could be regulated by additional mechanisms. Our findings thus establish a paradigm for Wnt pathway activation in basal-like breast cancer that does not depend on oncogenic mutation of Wnt pathway components, as commonly seen in colorectal cancer, heptocellular carcinoma and other cancers 36, 40, 41, 59 . The Np63-FZD7-Wnt axis may represent a driving force for the initiation and maintenance of basal-like breast tumour, thus serving as a potential target for therapeutic intervention.
The cell of origin of TICs in different subtypes of breast cancer remains ill-defined despite some recent advances. Gene expression profiling and targeted disruption of BRCA1 in mouse models suggest that luminal progenitors are a likely target cell population of basal-like breast cancer harbouring BRCA1 mutations 1, 60, 61 . In the present study, heterozygous loss of Np63 reduces expansion of the MaSC-enriched P4 population in the pre-neoplastic mammary gland hyperplasia, as well as a reduction of the Thy-1 + TIC population in MMTV-Wnt1 tumours. These findings suggest that MaSCs may be the cell of origin in another subset of basal-like breast cancers that is dependent on the Np63-Fzd7-Wnt axis. Given the heterogeneity of basal-like breast cancers, it is not surprising that under the influence of different oncogenic events, distinct target cell populations in the normal gland may give rise to TICs in different subsets of basal-like breast cancer. It is also possible that during oncogenic transformation of luminal progenitors, MaSC-like features as well as elevated Np63 expression might be acquired in TICs or their pre-neoplastic precursors that eventually give rise to basal-like cancers (Fig. 8g) . Future studies are required to rigorously explore these various possibilities.
METHODS
Methods and any associated references are available in the online version of the paper. 
Animal studies. Animal procedures were conducted in compliance with the Institutional Animal Care and Use Committee (IACUC) of Princeton University. The Np63-GFP knock-in mouse model has been described previously 43 . For all experiments, Np63 gfp/+ ( Np63-heterozygote) and control littermate (wild type; WT) animals were used. MMTV-Wnt1 (C57/B6 background) animals were crossed to Np63 gfp/+ mice (C57/B6 background) to give rise to MMTV-Wnt1; Np63 +/+ and MMTV-Wnt1; Np63 gfp/+ females. For the cleared fat pad injection experiment, FVB or C57/B6 mice at 3 weeks old were anaesthetized and a small incision was made to reveal the mammary gland. Single-cell suspensions were injected into cleared inguinal (#4) mammary fat pads following the standard injection procedure 32 . For orthotopic primary tumour formation, FVB mice were used, because MMTV-Wnt1 or MMTV-cMyc animals for this experiment were on the FVB background. MMTV-Wnt1 or MMTV-cMyc tumour cells resuspended in 10 µl PBS/Matrigel (1:1) were injected directly into the mammary fat pad. MDA-MB-231 or SUM-1315 cells resuspended in 10 µl PBS/Matrigel (1:1) were injected in the mammary fat pad of immunocompromised NSG mice. The primary tumour growth was monitored weekly. We used 6-10 mice per experimental group in all animal experiments. All animals were of the same age and sex at the time of mammary epithelial cell injection or tumour cell injection. No statistical method was used to pre-determine sample size. The experiments were not randomized. There was no blinded allocation during experiments and outcome assessment. However, the technicians who performed the measurement of tumour size or repopulation percentage and area were blind to the allocation.
Limiting dilution assay. Single-cell suspensions of primary mammary epithelial cells (MECs) from WT and Np63
gfp/+ mammary glands at 6-7 or 9-10 weeks were sorted in combination with the Lin − , CD24 + and CD29 high markers to obtain MaSC-enriched P4 (Lin − CD24 + CD29 high ) cells, which were then injected into cleared mammary fat pads. The outgrowths were analysed at 6-8 weeks post-transplantation. Transplantation was performed with the indicated number of cells resuspended in 50% Matrigel and 50% PBS. The frequency of MaSCs in the transplanted cell suspension was calculated using L-calc software (StemCell Technologies) or ELDA (Extreme Limiting Dilution Assay) 50 . A single-hit model was also tested using ELDA and the value of the slope was 1. MaSC abundances were assumed to follow a Poisson distribution in limiting dilution assay, and generalized linear models using a log-log link function were used to derive repopulation frequency parameters. For the human MaSC-enriched population, we FACS-purified the basal cell population from healthy breast tissues obtained from reduction mammoplasties using previously described approaches 64 . For the competitive reconstitution assay, 2,000 MaSC-enriched populations (P4) isolated from actin-GFP and actin-DsRed mice were mixed in an equal ratio (1:1) either from control or experimentally manipulated cells and injected into cleared mammary fat pad.
Mammosphere/tumorsphere and 3D Matrigel colony-forming assays. Stem cells from the mammary gland were maintained and passaged in vitro as spheroids in suspension or as organoids in 3D Matrigel cultures. Mammosphere counts from either method over multiple passages represent self-renewal activity 8 . Cells were cultured as previously described 10 . Briefly, primary mammary epithelial cells from normal gland or tumour tissue were spin-infected and then plated either onto sixwell, ultralow-attachment plates (Corning) at a density of 10,000 cells or 20,000 cells per well for the mammosphere or tumorsphere assay. For the 3D colony-forming assay, cells were plated in reduced-growth-factor Matrigel (BD Biosciences) at a density of 10,000 or 20,000 cells.
Cell lines and culture conditions. HMLE cells were cultured in DMEM/F12
(1:1) media containing 5% horse serum, 10 µg ml −1 insulin, 20 ng nl −1 EGF, 100 ng ml −1 cholera toxin and 500 ng ml −1 hydrocortisone. Immortalized murine MECs (iMMECs) were cultured in F12 media containing 10% fetal bovine serum, 10 µg ml −1 insulin, 20 ng nl −1 EGF and 500 ng ml −1 hydrocortisone. Human MECs (Lonza) were cultured in media in accordance with the manufacturer's instructions.
Molecular cloning.
The pLEX plasmids (Open Biosystems) containing cDNAs for control-GFP, WT Np63, MT Np63 and WT Fzd7 were generated by routine molecular cloning techniques. The WT-Np63 and MT-Np63 cDNAs were subcloned from the pCMV-HA vector, to pLEX plasmids using BamHIXhoI/NotI restriction sites. Fzd7 cDNA was subcloned to pLEX plasmids using BamHI-MluI restriction sites. The DNA-binding-deficient MT Np63 represents an amino acid change R > W at position 304 and has been described before 43 . The 500-bp Fzd7 enhancer segment was isolated from human genomic DNA by PCR and cloned into pGL3-basic (Promega) using KpnI-SpeI restriction sites. For retroviral-mediated knockdown studies, shRNAs targeting isoform-specific and/or a common region of human and mouse p63 were designed using shRNA_selector as described previously 65 . The sense and antisense oligonucleotides of each shRNA were annealed and cloned into the pRetroSuper vector using BglII and HindIII sites 66 . Empty vector was used as the negative control. For lentivirus-mediated isoform-specific shRNAs, the XhoI/NheI fragment containing an H1-driven shRNA expression cassette was transferred from the pRetroSuper vector to the lentiviral vector pLEIGW, so the resulting lentiviral vector expresses shRNA and EGFP as a selection marker. For knockdown studies in mice, Fzd7 and p63 (both isoforms) targeting shRNA expression lentiviral vectors were purchased from Sigma-Aldrich. The targeting shRNA sequences are: 5 -GAGGCCAACTCGCAGTACTTTC-3 for Fzd7 and 5 -CCGTCAGAATACACACGGAAT-3 (p63 KD1) and 5 -CCC AGTATGTAGAAGATCCTA-3 (p63 KD2) for p63 respectively. Control plasmid containing a scrambled shRNA sequence was purchased from Sigma-Aldrich. For isoform-specific knockdown studies in mice, the targeting shRNA sequences are: 5 -GGCACCTGAATTCTGTTA-3 for Np63 KD1, 5 -GCACCTGAATTCTGT TAT-3 for Np63 KD2, 5 -GGTTACTTGAAGACTCTTA-3 for TAp63 KD1 and 5 -CCCATCTGTTGGTATCAAA-3 for TAp63 KD2.
For general and isoform-specific p63-KD studies in human cells, the targeting shRNA sequences are: 5 -CCCAGTATGTAGAAGATCCTA-3 for p63, 5 -GCAGCATTGATCAATCTTA-3 for Np63, 5 -CGACAAACAAGATTGAGA TTA-3 for TAp63, 5 -GGGAACAGCCATGCCCAGTATG-3 for p63 DBD, and 5 -CCGGCTGTTCGTCTACCTCTTCAT-3 for FZD7.
Viral production and infection. For lentivirus-mediated overexpression or knockdown studies, expression plasmids and shRNA constructs are described above. All plasmids were packaged into viruses using HEK293-T cells as packaging cell lines and helper plasmids VSVG and dR8.9 following standard protocols. Primary cells were spin-infected with virus-containing media supplemented with 2 µg ml −1 Polybrene for 2 h at 1,000g at 4 • C and then either plated in Matrigel or transplanted. Self-renewal activity of transduced MaSCs after transplantation was tested by their ability to regenerate functional mammary glands in virgin and pregnant mice as shown in Supplementary Fig. 1c . For HMLE cells, virally infected cells were selected with puromycin. The retroviral vectors were transfected into the H29 packaging cell line. Viruses were collected 48-72 h after transfection. Cells were infected with viral media in the presence of 5 µg ml −1 Polybrene. The infected cells were selected with puromycin.
Luciferase enhancer reporter assay. HMLE or iMMEC cells were seeded in 24-well plates 24 h before transfection. The following day, 600 ng of the WTNp63, MT-Np63 and WT-TA-p63 expression plasmids was co-transfected along with 400 ng of enhancer reporter plasmid (FZD7 enhancer or TK control) and 100 ng of internal control plasmid that constitutively expresses Renillaluciferase using Lipofectamine 2000 (Invitrogen). Cells were collected 24 h posttransfection and assayed for luciferase activity using the Glomax 96 microplate luminometer (Promega).
Wnt reporter assay. P4 cells were co-transduced with the 7TFC Wnt reporter 67 and either control, Np63 or TAp63 virus and then plated on gelatin. After 48 h, cells were treated with Wnt3A (R & D Systems) for 24 h. Cells were then selected for infected cells by sorting for mCherry and a luciferase assay was performed as previously described 67 . MDA-MB-231 cells were co-transduced with the 7TFC Wnt reporter 67 and either control, Np63-KD, TAp63-KD or Fzd7-KD virus and then plated. The luciferase assay was performed using a method similar to that for MaSCs.
Protein extraction and western blot analysis. Proteins were extracted from primary epithelial cell cultures and cell lines in RIPA buffer as previously described 10 . Western blot analysis was performed using a standard protocol. Antibodies and dilutions used are listed in Supplementary Table 2 .
Histological analysis, immunohistochemistry and immunofluorescence. For histological analysis, mammary gland specimens were processed as previously described 10 . Antibodies and dilutions used are listed in Supplementary Table 2 . DAPI was used to stain nuclei. Confocal images were taken using a Nikon A1 confocal microscope.
Immunohistochemical analysis of breast tumour specimens. Normal mammary tissues and breast tumour specimens used in the study were deidentified samples and were considered exempt by Institutional Review Boards of Princeton University and the Rutgers New Jersey Medical School, as well as the Area Vasta Romagna Ethics Committee (CEIIAV IRST IRCCS), Meldola, Italy. Immunohistochemistry of Np63 and FZD7 was performed by the Tissue Analytic Core Facility in the Rutgers Cancer Institute of New Jersey. Anti-Np63, anti-TAp63 and anti-FZD7 (Sigma-Aldrich, Cat. no. AV41251) were first optimized on regular human breast tissue slides using a Ventana Medical Systems Discovery XT automated immunostainer. Slides were processed as previously described 10 . Anti-Np63, anti-TAp63 and anti-FZD7 antibody were applied at dilutions of 1:80, 1:80 and 1:100 respectively and incubated at room temperature for two hours. Twelve primary human breast tumour samples were used for immunohistological staining in our Np63/FZD7 expression correlation study. Each sample was scored as negative (0), low (1), medium (2) or high (3) according to Np63 and FZD7 staining abundance. A tumour with a mean score larger than 1 was considered to be positive for the expression of the gene. Pearson's coefficient test was performed to assess statistical significance.
qRT-PCR analyses. Total RNA was isolated from primary cells using the Qiagen RNA extraction kit in accordance with the manufacturer's instructions. Realtime RT-PCR was performed on an ABI 7900 96 HT series PCR machine (Applied Biosystems) using SYBR Green Supermix (Bio-Rad Laboratories). The gene-specific primer sets were used at a final concentration of 0.2 µM and their sequences are listed in Supplementary Table 3 . All qRT-PCR assays were performed in duplicate in at least three independent experiments using three different tissue samples.
Microarray analysis. The P4, P5 and P6 subpopulations of MECs were isolated from the mammary glands (4 mammary glands from each group) of virgin mice. MECs were isolated using FACS as described in ref. 32 . The unsorted whole MECs or sorted P4 cells from WT and Np63 gfp/+ mice (C57/B6 strain) at 7 weeks of age were prepared as described. RNA was collected from these samples using the RNAeasy Mini Kit (Qiagen) according to the manufacturer's instructions. The gene expression profiles of various populations of MECs from the WT and Np63 gfp/+ mice were determined using the Agilent mouse GE 4×44K two-colour microarrays system (Agilent, G4122F), following the manufacturer's instructions. Briefly, the RNA samples and universal mouse reference RNA (Agilent 740100) were labelled with CTP-cy5 and CTP-cy3, respectively, using the Agilent Quick Amp Labelling Kit. Labelled test and reference RNA samples were mixed in equal proportions, and hybridized to the mouse GE 4×44K array. The arrays were scanned with an Agilent G2565BA scanner and raw data were extracted using Agilent Feature Extraction software (v9.5). Data were analysed using the GeneSpring GX software (Agilent). The expression value of individual probes refers to the Log2(Cy5/Cy3) ratio.
Gene set enrichment analysis (GSEA). Gene set enrichment analysis (GSEA) v2.0 was used to perform the GSEA on various functional and/or characteristic gene signatures as described in a previous study 10 . Normalized microarray expression data were rank-ordered by differential expression between cell populations and/or genetic background as indicated, using the provided ratio of classes (that is, fold change) metric. Two independent MaSC-specific gene signatures were used to characterize MaSC characteristics. Both are defined by significantly upregulated genes (P < 0.05 and FC >3) in MaSC-enriched subpopulations from MECs of WT mice. The 'MaSC signature from current study' is derived from the microarray data collected from our laboratory as described in this study (GSE47493). The genes qualify by showing a >3-fold upregulation in P4 compared with both P5 and P6 of WT mice. The other MaSC signature is derived from published data set GSE22446. Other gene signatures used in GSEA were obtained from the MSigDB database v3.0 (September 2010 release).
Clinical data set analysis. To develop a conserved gene expression readout for Np63 activity, we first interrogated microarray data sets comparing both MECs as well as the MaSC-enriched (P4) subpopulation of WT and Np63 gfp+/− mice. Using log 2 -transformed and median-centred microarray data, we defined the Np63 signature as the gene expression values of all genes with >1.5-fold change between MECs and P4 cells compared with their corresponding WT control cells. This corresponded to 125 genes upregulated or downregulated in both MECs and P4 cells compared with the WT. To reduce each gene to one expression value, we took the average of its expression in MECs and in P4 cells. We then applied this signature to log 2 -transformed and median-centred microarray data from the EMC286 clinical breast cancer data set 47 . To predict Np63 activity in a given patient, we used overall Pearson correlation of patient gene expression values and Np63 signature gene expression values for all genes in the experimentally derived Np63 signature. The Pearson correlation coefficient values were used as a given patient's Np63 signature score. We then defined Np63-high and Np63-low patients as those with above and below median Np63 signature scores, respectively.
To analyse the expression of different isoforms of p63 in breast cancer patients, we used the TCGA breast invasive carcinoma (BRCA) exon expression RNAseq data set 46 . We downloaded the expression data set (data set ID TCGA_BRCA_exp_HiSeqV2_exon) and patient sample characteristics from the UCLA cancer browser (https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/). The expression levels of isoform-specific exons were used to represent the expression of specific isoforms. The Pearson correlation coefficiency was calculated to measure the correlation between genes. For grouping, 1 base unit RPKM (Reads Per Kilobase of exon model per Million mapped reads) was set as the cutoff, so fewer than 1 RPKM is defined as absent (or undetectable) and more than 1 RPKM is defined as present (or detectable).
In silico analysis. The sequence conservation between the mouse and human FZD7 enhancer was examined using the VISTA computational tools for comparative genomics (http://genome.lbl.gov/vista/index.shtml).
Chromatin immunoprecipitation. Human MECs (Lonza) or MMTV-Wnt1 primary cells were grown to 80% confluence and cells were then crosslinked with 1% formaldehyde and processed. The crosslinking, immunoprecipitation, washing, elution, reverse crosslinking, and proteinase K treatment were performed according to the manufacturer's directions described in the Magna ChIP G Chromatin Immunoprecipitation Kit from Millipore. Antibodies used were anti-4A4, H-129 (Santa Cruz) or normal rabbit IgG. Purified immunoprecipitated DNA was used for real-time qPCR. Primers for ChIP PCR are: 5 -TATCAGCATTCCAGGCCCAC-3 (forward) and 5 -TTCCTGGGAGAACAATCGCC-3 (reverse) for human FZD7 ; 5 -AATGAGGCAAACACCCCCTC-3 (forward) and 5 -CTCCGGGGGATTAAA GGTGG-3 (reverse) for mouse Fzd7 ; 5 -CGAGATCCCTCCAAAATCAA-3 (forward) and 5 -CCCAGCCTTCTCCATGG-3 (reverse) for human GAPDH and 5 -AACATCAAATGGGGTGAGG-3 (forward) and 5 -GGCCTTCTCCAT GGTGGT-3 (reverse) for mouse Gapdh.
Statistical analysis.
Results were generally reported as mean ± s.d. (standard deviation) as indicated in the figure legends. For comparisons of central tendencies, normally distributed data sets were analysed using unpaired (with the exception of analyses of cellular populations from paired contralateral injections) two-sided Student's t-tests under the assumption of equal variance. Non-normally distributed data sets were analysed using non-parametric Mann-Whitney U tests. Pearson's χ 2 tests were used for tumour incidence using ELDA software. To adjust for host effects, paired two-sided Student's t-tests assuming equal variance were used for experiments in which cellular populations were compared following matched contralateral injections of control and experimental cell types into the same mouse ( Supplementary Fig. 3g ). For tumour-free survival analyses, data were shown as Kaplan-Meier plots and significance was assessed by log-rank tests. Statistical analyses specific to limiting dilution Assays and GSEA are described above. All of the experiments with representative images (including western blot, FACS plot, histology and immunofluorescence) were repeated at least three times and representative images are shown.
Accession numbers for data sets. Microarray data generated in this study have been deposited at the NCBI Gene Expression Omnibus (http://www.ncbi. nlm.nih.gov/geo/) with the accession code GSE47493. Other published data sets used in this study are GSE22446 (MaSC signature) 63 and GSE2034 (EMC286 data set) 47 . The processed TCGA RNAseq data were obtained from the UCLA Cancer Browser https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/. Data set ID: TCGA_BRCA_exp_HiSeqV2_exon, version 2013-12-18. 
